NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, News, & Analysis

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals announced that its Board of Directors has authorized a stock repurchase program on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 3.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board believes its shares are undervalued.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings results on Wednesday, October, 24th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts' consensus estimates of $1.74 by $0.28. The biopharmaceutical company earned $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. Alexion Pharmaceuticals had a return on equity of 16.60% and a net margin of 3.90%. The business's revenue was up 19.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.44 EPS. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals updated its FY18 earnings guidance on Wednesday, October, 24th. The company provided earnings per share (EPS) guidance of $7.45-7.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.24. The company issued revenue guidance of $4.02-4.05 billion, compared to the consensus revenue estimate of $4.04 billion.Alexion Pharmaceuticals also updated its FY 2018 guidance to $7.45-7.60 EPS.

18 brokers have issued 1 year price objectives for Alexion Pharmaceuticals' stock. Their predictions range from $123.00 to $190.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $163.1176 in the next year. This suggests a possible upside of 49.1% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 2 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.

News articles about ALXN stock have trended somewhat positive this week, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alexion Pharmaceuticals earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the near term.

Some companies that are related to Alexion Pharmaceuticals include AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG), Allergan (AGN), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA) and UCB (UCBJF).

Alexion Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (9.46%), BlackRock Inc. (7.31%), Vanguard Group Inc. (7.09%), Vanguard Group Inc (7.09%), Jennison Associates LLC (3.87%) and Clearbridge Investments LLC (2.32%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, Edward Miller, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Leonard Bell, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Banco Santander S.A., Bank of Montreal Can, Bank of New York Mellon Corp, AXA, Mitsubishi UFJ Trust & Banking Corp, Swedbank and Marshall Wace LLP. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.

ALXN stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, American Century Companies Inc., Iridian Asset Management LLC CT, Clearbridge Investments LLC, First Trust Advisors LP, Wells Fargo & Company MN and Point72 Asset Management L.P.. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $109.43.

Alexion Pharmaceuticals has a market capitalization of $25.08 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.

The official website for Alexion Pharmaceuticals is http://www.alexion.com.

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]